Medical Oncologist focused on GI & Endocrine Malignances. Vall Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO). Teknon Cancer Institute.
Palau-solità I Plegamans
Joined May 2017
- Tweets4.1K
- Following319
- Followers2.7K
- Likes8.8K
Jaume Capdevila retweeted
🔬 Nous avenços en #CàncerDeTiroide a #ESMO26!
@Ja_Capdevila i @Alej_GarciaMD, del #VHIO, van presentar resultats dels assajos LIBRETTO-531 i SETHY, que impulsen l’oncologia de precisió i exploren noves opcions de tractament.
➡️ linke.to/ESMO2026TiroideVHIO…
Jaume Capdevila retweeted
#ESMO26 🧬 LIBRETTO-531 | Phase III
👥 291 pts | 1L advanced RET-mutant MTC
💊 Selpercatinib vs cabozantinib/vandetanib
📈 4-year PFS: 67.4% vs 20.5%
HR 0.21
🎯 4-year OS: 87.1% vs 66.8%
HR 0.34 (p<0.0001)
✅ 4-year PFS2: 85.9% vs 54.6%
HR 0.23
💡 Significant OS benefit confirms selpercatinib as the preferred 1L standard!
@OncoAlert
Jaume Capdevila retweeted
#ESMO26 Proffered Paper: NETS and endocrine tumors. “The boss”@Ja_Capdevila long term survival of Libretto-531
#ESMO26 🧬 LIBRETTO-531 | Phase III
👥 291 pts | 1L advanced RET-mutant MTC
💊 Selpercatinib vs cabozantinib/vandetanib
📈 4-year PFS: 67.4% vs 20.5%
HR 0.21
🎯 4-year OS: 87.1% vs 66.8%
HR 0.34 (p<0.0001)
✅ 4-year PFS2: 85.9% vs 54.6%
HR 0.23
💡 Significant OS benefit confirms selpercatinib as the preferred 1L standard!
@OncoAlert
Jaume Capdevila retweeted
🇪🇸 #ESMO26 🧬 SETHY | Phase II – Spanish GETNE study
💊 Sacituzumab govitecan (TROP2 ADC)
🔬 DTC (n=24):
🎯 ORR 4.4% | mPFS 5.5 mo
🔬 ATC (n=13):
🎯 ORR 16.7% | mPFS 2.9 mo
💡 Preliminary activity in ATC. TROP2 biomarker analysis awaited!
👏 Great work by @GrupoGetne
@OncoAlert
Jaume Capdevila retweeted
#ESMO26 ra🔬Two oral by VHIO– @Getne investigators!
🔹 @Ja_Capdevila | LIBRETTO-531: after long followup, Selpercatinib improves survival in RET-mutant medullary thyroid cancer.
🔹 @Alej_GarciaMD | SETHY @GrupoGetne : 1st anti-TROP2 ADC trial in IV thyroid cancer.
🌿Great word 🩺
Jaume Capdevila retweeted
#ESMO26
🚀 LIBRETTO-531 is a randomized phase 3 study comparing 1L selpercatinib vs physician’s choice of Cabozantinib or Vandetinib
🗣️ @Ja_Capdevila
📌 OS at 48m is 87.1 vs 66.8% HR 0.338
📌 PFS at 48m 67.4 vs 20.4% HR 0.205
☣️ gran, deu mouth, diarrhea
@OncoAlert @myESMO @ASCO @_SEOM @VHIO @brunolarvol
👇🏽👇🏽 – at Coslada, España
Jaume Capdevila retweeted
#ESMO26
🚀SETHY (GETNE T2318) is a single-arm, multicenter, phase 2 trial for ATC/DTC with Sacituzumab govitecan
🗣️ @Alej_GarciaMD
Congratulations on an interesting ITT trial
✔️ More efficacy at increasing H-score for #TROP2
☣️No new safety signals
Discussed by Dr. Nunes
@OncoAlert @myESMO @ASCO @_SEOM @VHIO @brunolarvol
👇🏽👇🏽 – at Madrid, Spain
Jaume Capdevila retweeted
🔬 New advances in #ThyroidCancer at #ESMO26!
#VHIO’s @Ja_Capdevila and @Alej_GarciaMD presented findings from the #LIBRETTO-531 and #SETHY trials, supporting precision oncology and exploring new treatment options.
➡️ linke.to/ESMO2026TiroideVHIO
Jaume Capdevila retweeted
🔬 ¡Nuevos avances en #CáncerDeTiroides en #ESMO26!
@Ja_Capdevila y @Alej_GarciaMD, del #VHIO, presentaron resultados de los ensayos LIBRETTO-531 y SETHY, que impulsan la oncología de precisión y exploran nuevas opciones de tratamiento.
➡️ linke.to/ESMO2026TiroideVHIO…
Jaume Capdevila retweeted
🔥Presidential session at ESMO 2026 🔥
HARMONi-GI1 ph-3: Ivonescimab + CTx vs durvalumab + CTx as 1L for BTC
#ESMO26 #ESMOAmbassadors
👉ORR: 53.8 vs. 32.5 %
👉mPFS: 8.4 vs 5.8 mo
👉mOS: 14.9 vs. 12.1 mo
🧐 Very promising Chinese data, would be great to see data in a global population
@myESMO @ASCO
Jaume Capdevila retweeted
We at @getne should be very proud of what the up-and-coming young generation is achieving. A magnificent presentation of the #CABOTHYROID study findings by @JHernando3 at #ESMO26
@myESMO @OncoAlert
Jaume Capdevila retweeted
#ESMO26 🇪🇸 🧬 GETNE-CABOTHYROID | Fase II
presentado por @JHernando3
👥 41 pacientes | Cáncer de tiroides refractario a radioyodo
💊 Cabozantinib
🎯 ORR 25,6%
📈 SLP 16,1 meses
⏳ DoR 18,4 meses
🧬 Metilación de cfDNA: potenciales biomarcadores predictivos.
🔬 ¡Seguimos impulsando la investigación desde @GrupoGetne
Jaume Capdevila retweeted
👏 Huge congratulations to my friend @JHernando3 on presenting the GETNE-T2216/CABOTHYROID trial at #ESMO26!
Promising results with cabozantinib in advanced thyroid cancer: ORR 24%, DCR 89.7% and median PFS 16.1 months.
Great work by @GrupoGetne 🇪🇸! @Ja_Capdevila @OncoAlert
Jaume Capdevila retweeted
Great to present the results of the @GrupoGetne SPAINTRK study at #ESMO2026!
Our real-world data in spanish population support the efficacy and durability of larotrectinib across NTRK fusion-positive solid tumors.
Proud of this collaborative effort!
Jaume Capdevila retweeted
👏👏 Amazing rapid orals session in #Neuroendocrinetumirs at #ESMO26!!!!
Congratulations to the presenters and the discussants!! New Pb-based Radioligands and DLL3 driven drugs are promising new strategies in the field.
@Ja_Capdevila @OncoThor @GrupoGetne @myESMO @OncoAlert @Netespana
Jaume Capdevila retweeted
First-line chemo + #Obrixtamig from #DAREON7 by @Ja_Capdevila
Results by DLL3 status: high vs low
More CRS if DLL3 high?
ORR higher in DLL3 high, but still 65% in DLL3 low (good)
DAREON-NEC-1 - recruiting in Spain (including @Hospital_FJD)
@myESMO #ESMO26 #ESMOAmbassadors
Jaume Capdevila retweeted
📣 Desde GETNE damos visibilidad a #NETPRACTICE 🌍
🔬 ¿Tratas pacientes con TNE? ¡Participa en esta encuesta internacional sobre práctica clínica y necesidades no cubiertas!
🌎 70 respuestas | 12 países
⏱️ 12–15 min | 🔒 Anónima
📊 Primeros resultados en #ENETS
✍️ forms.gle/twwrLCty4Z27ktCC6
@Alej_GarciaMD @Ja_Capdevila @JHernando3
Jaume Capdevila retweeted
🚨 FDA approval for dostarlimab in locally advanced dMMR/MSI-H rectal cancer!
This was based on AZUR-1, with full data coming at @myESMO. #ESMO26
No recurrences among responders after more than 2 years of median follow-up!
We know immunotherapy works, and when patients respond, those responses can be incredible.
I’ve been using immunotherapy with curative intent in these patients, and I haven’t been disappointed.
The fact that we’re potentially curing solid tumors with systemic therapy alone, without chemotherapy, radiation, or surgery, is magical.
Looking forward to the full data and seeing this approach become more broadly available to patients.
@OncoAlert @Onco_Nexus @TheGutOncLab
fda.gov/news-events/press-an…
Jaume Capdevila retweeted
Pancreatic Adenocarcinoma, Version 4.2026: NCCN Clinical Practice Guidelines in Oncology
🎯Tumour NGS is recommended for every patient who is a candidate for anticancer therapy, with RNA sequencing added because it detects fusions better.
- Neoadjuvant PAXG is listed as a useful-in-certain-circumstances option on the Italian Phase 3 result against mFOLFIRINOX (median EFS 16.0 vs 10.2 months, HR 0.63).
⚠️After neoadjuvant therapy, resection decisions are now framed by biological response (RECIST, CA 19-9, clinical status) rather than vascular contact alone.
🩸 The panel declines to make a consensus recommendation on postoperative ctDNA.
#NCCN #GIOnc #PDAC
jnccn.org/view/journals/jncc…
